Get In Touch
Have any questions or comments about the content you see on this page?
Our News
October 25, 2019
Alnylam has been named the #1 science employer in biopharma for 2019 by Science Magazine and Science Careers. This is our first appearance on the list.
Results were based on 7,658 surveys of people in the industry who rated companies on attributes such as corporate image, leadership and direction, work culture/environment, and academic and intellectual challenge. According to Science, the 2019 global survey results were based on responses from North America (72 percent), Europe (19 percent) and the Asia/Pacific Rim (7 percent).
Science has long recognized innovative leaders within our industry, and we are thrilled to be ranked at the top of this esteemed list. It’s quite gratifying to have our science and culture recognized as we work hard to discover and develop the next wave of RNAi therapeutics for patients with serious diseases.” – Akshay Vaishnaw, M.D., Ph.D., President, Research & Development, Alnylam Pharmaceuticals.
From Science Magazine:
"The 17th annual Top Employers Survey features a surprise: Alnylam Pharmaceuticals, an RNA-interference therapeutics company headquartered in Cambridge, Massachusetts, earned the No. 1 spot in its first appearance in the survey rankings. Some responses from the biotechnology and pharmaceutical industry are similar to those in previous surveys, however. Respondents valued innovation above all, while noting industry changes around drug pricing, regulations, and policies as well as an increasing emphasis on artificial intelligence and machine learning.
Followers of the annual Top Employers Survey from Science Careers will notice something new this year. The highest ratings in 2019 went to newcomer Alnylam Pharmaceuticals. The U.S.-based company of more than 1,200 employees develops RNA-interference (RNAi) therapies. In the three previous years, the top employer was Regeneron Pharmaceuticals in New York, which is No. 2 this year, followed by the Delaware-based pharmaceutical company Incyte. “We’re very excited,” says Alnylam CEO John Maraganore regarding the company’s Top Employer status. “We’ve grown a lot lately and our success depends on having a highly engaged team.”
You can read more from Science Magazine here.
Have any questions or comments about the content you see on this page?
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site